Immunic to Participate in Investor and Medical Conferences in May

Rhea-AI Summary

Immunic (Nasdaq: IMUX) will attend investor and medical conferences in May 2026, including Bio€quity Europe (May 4-6, 12-13) and the CMSC Annual Meeting (May 27-29).

Management will hold one-on-ones at Bio€quity; Immunic will present one late-breaking poster and two posters at CMSC on May 28 and staff the booth #307.

News Market Reaction – IMUX

-4.09%

19 alerts

-4.09% Session close to close

-13.3% Trough in 52 min

$136.62M Market Cap

0.4x Rel. Volume

In the Apr 30 session, IMUX declined 4.09%, reflecting a moderate negative market reaction. Argus tracked a trough of -13.3% from its starting point during tracking. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, April 30, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor and medical conferences in May:

• May 4-6 and 12-13: 26th Bio€quity Europe. Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, and Jessica Breu, Vice President Investor Relations and Communications at Immunic, will attend and host one-on-one investor meetings at this conference taking place in Prague, Czech Republic and virtually. To schedule a meeting, please use the Bio€quity Europe conference portal or contact Jessica Breu at: jessica.breu@imux.com.
  
  
• May 27-29: 2026 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting. Members of Immunic's management, medical and preclinical teams will attend this meeting in Charlotte, NC. One late-breaking poster and two additional posters have been accepted for presentation and will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations. Additionally, the team will be available throughout the event at booth #307.

Late-Breaking Poster Presentation:

• Title: Novel Unified Statistical Analyses for Confirmed Disability Changes In Multiple Sclerosis for Capturing Possible Neuroprotective Effects
• Presenting Author: James Myles, Global Head of Biostatistics at Immunic
• Abstract ID: 11244
• Poster Board Label: LBA14
• Session Date: Thursday, May 28, 2026
• Session Time: 5:00-7:00 pm ET
• Location: Exhibit Hall

Poster Presentations:

• Title: Effect of Vidofludimus Calcium, a Direct Nurr1 Activator and Selective DHODH Inhibitor, on Patient-Reported Outcomes (PRO) in Progressive MS: Data from Phase 2 CALLIPER Trial
• Presenting Author: Julie Korich, Ph.D., Senior Medical Director, Medical Affairs at Immunic
• Abstract ID: 10843
• Poster Board Label: DMT10
• Session Date: Thursday, May 28, 2026
• Session Time: 5:00-7:00 pm ET
• Location: Exhibit Hall B
  
  
• Title: Safety and Tolerability of Vidofludimus Calcium, a Direct Nurr1 Activator and Selective DHODH Inhibitor: Data from Phase 2 CALLIPER Trial
• Presenting Author: Alex Lublin, Ph.D., Senior Medical Director, Medical Affairs at Immunic
• Abstract ID: 10995
• Poster Board Label: DMT11
• Session Date: Thursday, May 28, 2026
• Session Time: 5:00-7:00 pm ET
• Location: Exhibit Hall B

About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026. It has already shown therapeutic activity in phase 2 clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). The company's development pipeline also includes earlier-stage programs, including IMU-856 and IMU-381, aimed at building a broader therapeutics platform addressing neurodegenerative, chronic inflammatory, and autoimmune-related diseases. For further information, please visit: www.imux.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in investor and medical conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company's products or product candidates, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026, and in the company's subsequent filings with the SEC. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.

Contact Information

Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com

US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com

US Media Contact
KCSA Strategic Communications
Caitlin Kasunich
+1 212 896 1241
ckasunich@kcsa.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/immunic-to-participate-in-investor-and-medical-conferences-in-may-302758603.html

SOURCE Immunic, Inc.

FAQ

When will Immunic (IMUX) be at Bio€quity Europe in May 2026?

Immunic will attend Bio€quity Europe on May 4-6 and May 12-13, 2026. According to Immunic, CEO Daniel Vitt and VP Jessica Breu will host one-on-one investor meetings in Prague and virtually; meetings can be scheduled via the conference portal or by contacting investor relations.

What will Immunic present at the CMSC Annual Meeting May 27-29, 2026?

Immunic will present one late-breaking poster and two additional posters at CMSC on May 28, 2026. According to Immunic, poster topics include statistical analyses for disability changes and Phase 2 CALLIPER data on vidofludimus calcium safety and patient-reported outcomes.

Who are the presenting authors for Immunic posters at CMSC 2026?

Presenting authors include James Myles, Julie Korich, and Alex Lublin on May 28, 2026. According to Immunic, James Myles will present the late-breaking analysis while Julie Korich and Alex Lublin will present CALLIPER trial results in Exhibit Hall B.

How can investors schedule meetings with Immunic (IMUX) at Bio€quity Europe?

Investors can schedule meetings via the Bio€quity Europe conference portal or contact Jessica Breu by email. According to Immunic, Jessica Breu at jessica.breu@imux.com is the designated contact for arranging one-on-one investor meetings during the event.

Where and when are Immunic poster sessions scheduled at the CMSC Annual Meeting?

All Immunic poster sessions are scheduled for Thursday, May 28, 2026 from 5:00-7:00 pm ET in the Exhibit Hall. According to Immunic, the late-breaking poster is labeled LBA14 and the two CALLIPER posters are labeled DMT10 and DMT11 in Exhibit Hall B.